

## Pubblicazioni su Riviste Scientifiche Internazionali indicizzate – Dott. Marco Galluzzo

- 1) Talamonti M, Galluzzo M, Chiricozzi A, et al. Ustekinumab for treatment of plaque psoriasis in patient with Down Syndrome. *Journal of Drugs in Dermatology (JDD)* 2012 Aug;11(8):1000-2. ISSN: 1545-9616
- 2) Talamonti M, Galluzzo M, Botti E, et al. Potential role of HLA-Cw6 in clinical response to anti-tumor necrosis factor alpha and T-Cell targeting agents in psoriasis patients. *Clinical Drug Investigation* 2013; 33:S71-S73
- 3) Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of Psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to IL12/23 blocker ustekinumab. *British Journal of Dermatology* 2013 Aug;169(2):458-63. ISSN: 0007-0963, doi: 10.1111/bjd.12331
- 4) Di Stefani A, Galluzzo M, Talamonti M, et al. Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. *Journal of Dermatological Case Reports* 2013 Mar 30;7(1):5-9. ISSN: 1898-7249, doi: 10.3315/jdcr.2013.1127
- 5) Saraceno R, Talamonti M, Galluzzo M, et al. Ustekinumab for erythrodermic psoriasis that appears in patient after the physical stress: a report of two cases. *Case Reports in Dermatology* 2013 Sep 26;5(3):254-9. ISSN: 1662-6567, doi: 10.1159/000348645
- 6) Boca AN, Talamonti M, Galluzzo M, et al. Genetic variations in IL6 and IL12B decreasing the risk for psoriasis. *Immunology Letters* 2013 Nov-Dec;156(1-2):127-31 ISSN: 0165-2478, doi: 10.1016/j.imlet.2013.09.028
- 7) Talamonti M, Galluzzo M, Bianchi L, et al. What happened after the clinical trials: long-term safety and efficacy of ustekinumab in the daily clinical practice. *Dermatology* 2014;229(4):324-32. ISSN: 1018-8665, doi: 10.1159/000365077
- 8) Talamonti M, Galluzzo M, De Piano E, et al. Genital psoriasis: successful therapy with tacrolimus. Case reports and literature review. *European Medical Journal* December 11, 2014. ISSN: 2054-6211
- 9) Galluzzo M, Talamonti M, Di Stefani A, et al. Linear psoriasis following the typical distribution of the sciatic nerve. *Journal of Dermatological Case Reports* 2015 Mar 31;9(1):6-11. ISSN: 1898-7249, doi: 10.3315/jdcr.2015.1189
- 10) Talamonti M, Galluzzo M, Chimenti S. Ustekinumab in the treatment of psoriasis. *Journal of Symptoms and Signs (JSS)* 2015; 4(1):32-41. ISSN: 2309-6195
- 11) Chimenti MS, Talamonti M, Novelli L, et al. Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature. *Journal of Dermatological Case Reports* 2015 Sep 30;9(3):71-5. ISSN: 1898-7249, doi: 10.3315/jdcr.2015.1207
- 12) Talamonti M, Galluzzo M, Servoli S, Chimenti S. Quality of life evaluation in psoriasis patients starting a biological treatment: the importance of a more comprehensive assessment of disease burden. *European Medical Journal* 2015;3(1):87-91. ISSN: 2054-6211
- 13) Galluzzo M, Boca AN, Botti E, et al. IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis. *Dermatology* 2016;232(2):230-6. ISSN: 1018-8665, doi: 10.1159/000441719
- 14) Talamonti M, Galluzzo M, Chimenti S, Costanzo A. HLA-C\*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up. *Journal of the American Academy of Dermatology* 2016 Feb;74(2):374-5. ISSN: 0190-9622, doi: 10.1016/j.jaad.2015.08.05

- 15) Galluzzo M, Andreani M, Testi M, et al. HLA-C\*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis. *Molecular Diagnosis & Therapy* 2016 Jun;20(3):227-30. ISSN: 1177-1062, doi: 10.1007/s40291-016-0199-y
- 16) Galluzzo M, D'Adamio S, Servoli S, et al. Tofacitinib for the treatment of psoriasis. *Expert Opinion on Pharmacotherapy*. 2016 Jul; 17(10):1421-33. ISSN: 1465-6566, doi: 10.1080/14656566.2016.1195812
- 17) Galluzzo M, D'Adamio S, Bianchi L, Talamonti M. Brodalumab for the treatment of psoriasis. *Expert Review of Clinical Immunology*. 2016 Dec; 12(12):1255-1271. ISSN: 1744-666X, doi: 10.1080/1744666X.2016.1246957
- 18) Galluzzo M, Talamonti M, Perino F, et al. Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis. *Journal of Dermatological Treatment*. 2017 Jun;28(4):299-303. ISSN: 0954-6634, doi: 10.1080/09546634.2016.1254326
- 19) Talamonti M, Galluzzo M, Zangrilli A, et al. HLA-C\*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. *Molecular Diagnosis & Therapy*. 2017 Jun;21(3):295-301. ISSN: 1177-1062, doi: 10.1007/s40291-017-0261-4.
- 20) Talamonti M, Galluzzo M, Servoli S, et al. Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. *Dermatology*. 2016;232(6):648-654. ISSN: 1018-8665, doi: 10.1159/000453661
- 21) Talamonti M, Galluzzo M, Van Den Reek JM, et al. Role of HLA- C\*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. *British Journal of Dermatology*. 2017 Aug;177(2):489-496. ISSN: 0007-0963, doi: 10.1111/bjd.15387
- 22) Galluzzo M, D'adamio S, Bianchi L, Talamonti M. Tildrakizumab for treating psoriasis. *Expert Opinion on Biological Therapy*. 2017 May; 17(5):645-657. ISSN: 1471-2598, doi: 10.1080/14712598.2017.1304537
- 23) Talamonti M, D'Adamio S, Bianchi L, Galluzzo M. The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature. *Molecular Diagnosis & Therapy*. 2017 Oct;21(5):467-480. ISSN: 1177-1062, doi: 10.1007/s40291-017-0274-z.
- 24) Galluzzo M, Talamonti M, D'Adamio S, Bianchi L. Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis. *Expert Opinion on Drug Metabolism & Toxicology*. 2017 Jun;13(6):679-691. doi: 10.1080/17425255.2017.1325874.
- 25) Ventura A, Mazzeo M, Gaziano R, et al. New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. *Drug Design, Development and Therapy*. 2017 Aug 30;11: 2527-2535. doi: 10.2147/DDDT.S136986.
- 26) Galluzzo M, D'Adamio S, Pastorino R, et al. Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients. *Expert Opinion on Biological Therapy*. 2018 Mar;18(3):229-235. ISSN: 1471-2598, doi: 10.1080/14712598.2018.1419183
- 27) Galluzzo M, D'Adamio S, Bianchi L, Talamonti M. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections. *Expert Opinion on Drug Metabolism & Toxicology*. 2018 Feb;14(2):197-206. ISSN 1742-5255:2, 197-206, doi: 10.1080/17425255.2018.1420162
- 28) D'Adamio S, Talamonti M, Bianchi L, Galluzzo M. Photo-recall reaction to gemcitabine. *Archive of Clinical Cases*. 2017 Dec 30. ISSN: 2360-6975 <http://dx.doi.org/10.22551/2017.17.0404.10113>.

- 29) Chimenti MS, Ortolan A, Lorenzin M, et al. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. *Clinical Rheumatology*. 2018 Feb;37(2):397-405. doi: 10.1007/s10067-017-3953-6.-6.
- 30) Galluzzo M, D'Adamio S, Bianchi L, Talamonti M. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. *Journal of Dermatological Treatment*. 2019 Feb;30(1):40-44. doi: 10.1080/09546634.2018.1468066.
- 31) Costanzo A, Bianchi L, Flori ML, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. *British Journal of Dermatology* 2018 Nov;179(5):1072-1080. doi: 10.1111/bjd.16705.
- 32) Talamonti M, Galluzzo M, Bernardini N, et al. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. *Journal of the European Academy of Dermatology and Venereology*. 2018 Oct;32(10):1737-1744. doi: 10.1111/jdv.15077.
- 33) Galluzzo M, Talamonti M, De Simone C, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. *Expert Opinion on Biological Therapy*. 2018 Jul;18(7):727-735. doi: 10.1080/14712598.2018.1481503.
- 34) Galluzzo M, D'Adamio S, Campione E, et al. A safety evaluation of guselkumab for the treatment of psoriasis. *Expert Opinion on Drug Safety*. 2018 Jul;17(7):741-751. doi: 10.1080/14740338.2018.1488963.
- 35) Galluzzo M, D'Adamio S, Campione E, et al. Treating a Multidrug-Resistant Psoriatic HLA-C\*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy. *Molecular Diagnosis & Therapy*. 2018 Dec;22(6):717-721. 2018 Dec;22(6):717-721. doi: 10.1007/s40291-018-0354-8.
- 36) Puviani M, Galluzzo M, Talamonti M, et al. Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial. *Int J STD AIDS*. 2019 Feb;30(2):131-136. doi: 10.1177/0956462418797874.
- 37) Galluzzo M, D'Adamio S, Campione E, et al. A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. *J Dermatolog Treat*. 2018 Sep 26:1-11. doi: 10.1080/09546634.2018.1524818.
- 38) Chimenti MS, Fonti GL, Conigliaro P, et al. Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study. *Medicine (Baltimore)*. 2019 Jan;98(4):e13955. doi: 10.1097/MD.00000000000013955.
- 39) Galluzzo M, D'Adamio S, Chimenti MS, et al. Successful treatment of psoriatic crumbly nails with ustekinumab. *Dermatol Ther*. 2019 May;32(3):e12914. doi: 10.1111/dth.12914.
- 40) Galluzzo M, D'Adamio S, Teoli M, et al. Biologic therapy for acrodermatitis continua of Hallopeau: successful treatment with secukinumab and review of the literature. *Dermatol Ther*. 2019 May;32(3):e12899. doi: 10.1111/dth.12899. Epub 2019 Apr 29.
- 41) Talamonti M, D'Adamio S, Galluccio T, et al. High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C\*06:02-positive psoriatic patients: HLA-C\*06:02/HLA-C\*04, in response to ustekinumab. *J Eur Acad Dermatol Venereol*. 2019 Oct;33(10):e364-e367. doi: 10.1111/jdv.15659. Epub 2019 May 20.
- 42) Mazzilli S, Giunta A, Galluzzo M, et al. Therapeutic monitoring of male genital lichen sclerosis: usefulness of reflectance confocal microscopy. *G Ital Dermatol Venereol*. 2019 May 14. doi: 10.23736/S0392-0488.19.06292-8. Online ahead of print.

- 43) Galluzzo M, D'Adamio S, Massaro A, et al. Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date. *Clin Cosmet Investig Dermatol*. 2019 May 1;12:311-321. doi: 10.2147/CCID.S165605. eCollection 2019.
- 44) D'Adamio S, Silvaggio D, Massaro A, et al. Pharmacotherapeutic management of psoriasis in adolescents and children. *Expert Opin Pharmacother*. 2019 Oct;20(14):1777-1785. doi: 10.1080/14656566.2019.1636032. Epub 2019 Jul 4.
- 45) Signa S, Campione E, Rusmini M, et al. Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab. *Pediatr Rheumatol Online J*. 2019 Jul 8;17(1):38. doi: 10.1186/s12969-019-0336-3.
- 46) van Vugt LJ, van den Reek JMPA, Meulewaeter E, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. *J Eur Acad Dermatol Venereol*. 2020 Jan;34(1):112-118. doi: 10.1111/jdv.15787. Epub 2019 Aug 5.
- 47) Lanna C, Mancini M, Gaziano R, et al. Skin immunity and its dysregulation in psoriasis. *Cell Cycle*. 2019 Oct;18(20):2581-2589. doi: 10.1080/15384101.2019.1653099. Epub 2019 Aug 15.
- 48) D'Adamio S, Silvaggio D, Lombardo P, et al. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. *Expert Opin Drug Saf*. 2019 Nov;18(11):1031-1041. doi: 10.1080/14740338.2019.1663168. Epub 2019
- 49) Rossi A, Muscianese M, Piraccini BM, et al. Italian Guidelines in diagnosis and treatment of alopecia areata. *G Ital Dermatol Venereol*. 2019 Dec;154(6):609-623. doi: 10.23736/S0392-0488.19.06458-7. Epub 2019
- 50) Galluzzo M, D'Adamio S, Silvaggio D, et al. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. *Expert Opin Biol Ther*. 2020 Jan;20(1):95-104. doi: 10.1080/14712598.2020.1684472. Epub 2019 Oct 30.
- 51) Galluzzo M, D'Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. *Expert Opin Biol Ther*. 2020 Feb;20(2):173-182. doi: 10.1080/14712598.2020.1708897. Epub 2019 Dec 27.
- 52) Campione E, Lanna C, Diluvio L, et al. Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. *Cell Cycle*. 2020 Feb;19(3):257-267. doi: 10.1080/15384101.2019.1707455. Epub 2020 Jan 5.
- 53) Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. *Expert Opin Biol Ther*. 2020 Jun;20(6):665-672. doi: 10.1080/14712598.2020.1727439. Epub 2020 Feb
- 54) Mazzilli S, Lanna C, Chiamonte C, et al. Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers. *J Dermatol*. 2020 Jun;47(6):578-582. doi: 10.1111/1346-8138.15293. Epub 2020 Apr 1.
- 55) D'Adamio S, Massaro A, Biocca S, et al. A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab. *Clin Exp Dermatol*. 2020 Aug;45(6):809-810. doi: 10.1111/ced.14276. Epub 2020 May 30.
- 56) Galluzzo M, Tofani L, Bianchi L, Talamonti M. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the

Covid-19 era. *Expert Opin Biol Ther.* 2020 Aug;20(8):829-830. doi: 10.1080/14712598.2020.1779217. Epub 2020 Jun 16.

57) Talamonti M, Tofani L, Bianchi L, Galluzzo M. Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? *Arch Dermatol Res.* 2020 Jul 9;1-2. doi: 10.1007/s00403-020-02103-z. Online ahead of print.

58) Galluzzo M, Tofani L, Lombardo P, et al. Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study. *J Clin Med.* 2020 Jul 9;9(7):2170. doi: 10.3390/jcm9072170.

59) Talamonti M, Galluzzo M, Chiricozzi A, et al. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. *J Eur Acad Dermatol Venereol.* 2020 Jul 31;10.1111/jdv.16841. doi: 10.1111/jdv.16841. Online ahead of print.

60) Talamonti M, Galluzzo M. Importance of genotyping patients for HLA-C\*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information. *Ann Transl Med.* 2020 Aug;8(15):971. doi: 10.21037/atm.2020.04.05.

61) Talamonti M, Galluzzo M, Chiricozzi A, et al. Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic: Risk Analysis from the PSO-BIO-COVID Observational Study. *Expert Opin Biol Ther.* 2020 Nov 20. doi: 10.1080/14712598.2021.1853698.

62) Galluzzo M, Talamonti M, Manfreda V, et al. Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies. *Expert Opin Biol Ther.* 2020 Nov 27. doi: 10.1080/14712598.2021.1849131.

63) Morelli M, Galluzzo M, Madonna S, et al. HLA-Cw6 and other HLA-C alleles, as well as MICB- DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. *Expert Opin Biol Ther.* 2020 Dec 28;1-12. doi: 10.1080/14712598.2021.1862082

64) Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. *J Eur Acad Dermatol Venereol.* 2021 Apr;35(4):958-964. doi: 10.1111/jdv.17094. Epub 2021 Jan 19.

65) Gisondi P, Talamonti M, Chiricozzi A, et al. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. *Dermatol Ther (Heidelb).* 2021 Feb;11(1):235-252. doi: 10.1007/s13555-020-00475-8. Epub 2021 Jan 11.

66) Patruno C, Fabbrocini G, Longo G et al. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study. *Am J Clin Dermatol.* 2021 Jul;22(4):581-586. doi: 10.1007/s40257-021-00597-5.

67) Talamonti M, Galluzzo M, Silvaggio D, et al. Quality of Life and Psychological Impact in Patients with Atopic Dermatitis. *J Clin Med.* 2021 Mar 21;10(6):1298. doi: 10.3390/jcm10061298.

68) Costanzo A, Russo F, Galluzzo M, et al. Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. *Acta Derm Venereol.* 2021 Oct 21;101(10):adv00576. doi: 10.2340/00015555-3816.

69) Papini M, Russo A, Simonetti O, et al. Diagnosis and management of cutaneous and anogenital lichen sclerosis: recommendations from the Italian Society of Dermatology (SIDeMaST). *Ital J Dermatol Venerol.* 2021 Oct;156(5):519-533. doi: 10.23736/S2784-8671.21.06764-X. Epub 2021 Apr 29.

70) Dattola A, Botti E, Galluzzo M, et al. HLA-C\*06:02 allele can influence clinical efficacy of certolizumab pegol? *Health Sci Rep.* 2021 May 4;4(2):e234. doi: 10.1002/hsr2.234. eCollection 2021 Jun.

- 71) Galluzzo M, Caldarola G, De Simone C, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. *Expert Opin Biol Ther.* 2021 Sep;21(9):1299-1310. doi: 10.1080/14712598.2021.1941862. Epub 2021 Jun 28.
- 72) Chiricozzi A, Talamonti M, De Simone C, et al. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry. *Allergy.* 2021 Jun;76(6):1813-1824. doi: 10.1111/all.14767. Epub 2021 Mar 9.
- 73) Talamonti M, Galluzzo M. Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents. *Expert Opin Biol Ther.* 2021 Nov;21(11):1535-1537. doi: 10.1080/14712598.2021.1965985. Epub 2021 Aug 17.
- 74) Galluzzo M, Chiricozzi A, Cinotti E, et al. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. *Expert Opin Biol Ther.* 2022 Mar;22(3):367-376. doi: 10.1080/14712598.2022.1988566. Epub 2021 Oct 12.
- 75) Galluzzo M, Talamonti M, Atzori L, et al. Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. *Expert Opin Biol Ther.* 2022 Apr;22(4):547-554. doi: 10.1080/14712598.2022.2029841. Epub 2022 Jan 20.
- 76) Chiricozzi A, Di Nardo L, Talamonti M, et al. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy. *Dermatitis.* 2022 May-Jun;33(3):e25-e29. doi: 10.1097/DER.0000000000000814. Epub 2021 Dec 10.
- 77) Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study. *Dermatol Ther.* 2022 Jun;35(6):e15488. doi: 10.1111/dth.15488. Epub 2022 Apr 11.
- 78) Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. *J Clin Med.* 2022 May 7;11(9):2631. doi: 10.3390/jcm11092631.
- 79) Galluzzo M, Talamonti M, Bernardini N, et al. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. *Expert Opin Biol Ther.* 2022 Dec;22(12):1585-1592. doi: 10.1080/14712598.2022.2090835. Epub 2022 Jun 22.
- 80) Papi C, Granata G, Galluzzo M, Iorio R. Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor. *Neurol Sci.* 2022 Nov 11. doi: 10.1007/s10072-022-06498-7. Online ahead of print.
- 81) Morelli M, Galluzzo M, Scarponi C, et al. Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis. *Vaccines (Basel).* 2022 Nov 21;10(11):1977. doi: 10.3390/vaccines10111977.
- 82) Gargiulo L, Ibba L, Malagoli P, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). *J Eur Acad Dermatol Venereol.* 2023 May;37(5):1017-1027. doi: 10.1111/jdv.18913. Epub 2023 Feb 8.
- 83) Galluzzo M, Marcelli L, Vellucci L, et al. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks. *Expert Opin Biol Ther.* 2023 Mar 27;1-12. doi: 10.1080/14712598.2023.2194485.